Pathology is moving from glass slides and microscopes to high-resolution digital images, cloud storage, and AI-assisted analysis. Labs, hospitals, and research institutions are all investing in the shift, and the numbers reflect it.

Market Size and Growth Forecast

According to Grand View Research, the global digital pathology market was valued at USD 1.5 billion in 2025. It is estimated at USD 1.6 billion in 2026 and is projected to reach USD 3.0 billion by 2033, a CAGR of 8.6% from 2026 to 2033.

• Regional leader: North America held the largest share, at 39.92% in 2025. The report attributes this to rising cancer prevalence, a push for workflow efficiency, and demand for faster diagnostics.
• Fastest-growing region: Asia Pacific is expected to post the highest CAGR through 2033, driven by rapid digitalization, growing healthcare investment, and rising cancer incidence.
• Leading product: Software accounted for 42.88% of revenue in 2025, while devices such as scanners and slide management systems are expected to grow fastest.

Key Drivers

1. Rising cancer prevalence and the need for precision. Pathologists increasingly need rich, shareable data to tailor therapies to individual patients. Digital pathology speeds up diagnosis, improves accuracy, and supports treatment recommendations. Oncology alone made up 52.02% of market revenue in 2025.
2. AI-powered image analysis. Pathologists once had to locate regions of interest in tissue samples by hand. AI now automates much of that work, cutting manual effort and the risk of human error. Falling hardware costs, growing venture capital interest, and the broader move toward big data in healthcare are strengthening this trend.
3. Integrated healthcare systems and partnerships. Health systems want patient records accessible across multiple facilities, which favors integrated digital pathology platforms. Vendors are responding with technology collaborations. One example is the February 2025 expansion of the partnership between Charles River Laboratories and Deciphex on image management and AI tools for toxicologic pathology.
4. Telepathology, healthcare IT adoption, and veterinary uptake. Organizations are adopting digital tools to cut costs, remove resource bottlenecks, and share content efficiently. Teleconsultations and collaborative research add momentum. Veterinary pathology is a growing niche as well, helped by fewer restrictions on diagnosing from scanned slides.
5. Drug discovery and precision medicine. Pharma and biotech companies use digital pathology for translational research, biomarker analysis, and companion diagnostics. Combining pathology imaging with genomics and spatial biology is opening new opportunities.

Get the Full Picture Download Free Sample Report for market data points, trend analysis, and forecasts.

Key Restraints

The source page is lighter on restraints than on drivers, but several barriers come through:

• Heavy regulation. The report rates the impact of regulation on the industry as high. Vendors must navigate rules on data integrity, patient privacy, and clinical compliance, including the U.S. FDA, HIPAA, and CLIA.
• High capital requirements. Meeting regulatory requirements takes significant investment, which can slow the growth of emerging players. Adopters also face costs for high-end scanners and IT infrastructure.
• Data management burden. Digitized slides generate massive data volumes that labs must store, manage, and secure.
• Workflow change and staff resistance. A case study of Portugal's IMP Diagnostics shows that labs must integrate digital tools without disrupting existing workflows, and that staff used to traditional microscopy may resist. A phased rollout, with training and gradual scaling, helped IMP overcome these hurdles.

Leading Application: Academic Research

By application, academic research led the market in 2025 with a 45.76% revenue share. Continued work on cancer therapies and wide use of digital pathology in research studies drive this dominance. Academic institutions are also partnering with technology providers. In November 2022, University Medical Center Utrecht partnered with Paige to deploy its AI application clinically and run a health economics study supporting reimbursement.

Disease diagnosis is the fastest-growing application segment. Chronic disease prevalence is rising, and manufacturers are focusing on rapid, novel diagnostic techniques. In April 2022, PreciseDx and The Michael J. Fox Foundation collaborated on AI-enabled digital pathology to help diagnose Parkinson's disease before severe symptoms appear.

The Bottom Line

With steady 8.6% growth, an expanding role for AI, and demand spanning research, diagnostics, and drug development, digital pathology is becoming core infrastructure for modern healthcare and life sciences. Vendors, labs, and investors who plan for the regulatory and data-management challenges early will be best placed to benefit.

Customize This Report to add regions, segments, or data points, with 20% free customization.